Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.

特立帕肽 医学 德诺苏马布 唑来膦酸 骨质疏松症 骨矿物 内科学 股骨颈 随机对照试验 泌尿科 外科
作者
Weiyang Wang,L-H Chen,Wendy Ma,Ruxu You
出处
期刊:PubMed 卷期号:27 (17): 8253-8268
标识
DOI:10.26355/eurrev_202309_33586
摘要

This study aims to compare the efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of women with postmenopausal osteoporosis.Randomized controlled trials (RCTs) were searched in Medline, Embase, and Cochrane up to April 2022. Statistical analysis was performed using R 4.1.3 software, and quality evaluation was conducted using Review Manager 5.3.51 RCTs containing 39,095 patients met our selection criteria. The efficacy results indicated that teriparatide was more effective than ibandronic acid in reducing vertebral fractures [relative risk (RR) = 0.536; 95% confidence interval (CI) (0.266, 0.998)]. Denosumab [mean difference (MD) = -4.19; 95% CI (-8.03, -0.355)] and teriparatide [MD = 4.64; 95% CI (1.60, 7.72)] showed better efficacy than ibandronic acid in improving spine bone mineral density (BMD). Denosumab showed better efficacy than teriparatide in improving radius BMD [MD = -4.14; 95% CI (-6.72, -1.54)], hip bone mineral density (BMD) [MD = -2.01; 95% CI (-3.80, -0.162)], and one-third radius BMD [MD = -3.63; 95% CI (-7.04, -0.151)]. Denosumab was associated with the greatest benefit in increasing radius BMD [the surface under the cumulative ranking curve area (SUCRA) = 0.999], hip BMD [surface under the cumulative ranking curve area (SUCRA) = 0.979], femoral neck BMD (SUCRA = 0.971), one-third radius BMD (SUCRA = 0.994) and preventing vertebral fractures (SUCRA = 0.806). Teriparatide was associated with the greatest benefit in preventing non-vertebral fractures (SUCRA = 0.927) and improving spine BMD (SUCRA = 0.899). The safety results indicated that teriparatide was safer than zoledronic acid regarding the risk of adverse events [RR = 0.958; 95% CI (0.919, 0.988)]. Teriparatide was associated with the greatest benefit in preventing adverse events (SUCRA = 0.908) and serious adverse events (SUCRA = 0.813).Our current results suggested that when considering both safety and efficacy, denosumab or teriparatide might be a better choice for women with postmenopausal osteoporosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
热情曲奇完成签到,获得积分10
1秒前
1秒前
无花果应助XLX采纳,获得10
1秒前
冷艳的靖柏完成签到,获得积分10
1秒前
刻苦惜霜完成签到,获得积分10
2秒前
kecheng应助催化打工人采纳,获得10
2秒前
3秒前
3秒前
NexusExplorer应助MCS采纳,获得10
3秒前
医无止境完成签到,获得积分10
3秒前
4秒前
姜一笑完成签到,获得积分20
4秒前
4秒前
4秒前
李爱国应助微辣不加香菜采纳,获得10
5秒前
5秒前
5秒前
5秒前
6秒前
Akim应助红木白花采纳,获得10
6秒前
6秒前
6秒前
鹿冶完成签到 ,获得积分10
7秒前
包佳梁发布了新的文献求助10
7秒前
ZZ完成签到,获得积分10
7秒前
7秒前
kyan发布了新的文献求助10
8秒前
sha完成签到,获得积分10
8秒前
8秒前
8秒前
9秒前
勤恳觅珍发布了新的文献求助10
9秒前
36456657发布了新的文献求助10
9秒前
9秒前
顾矜应助漂亮的振家采纳,获得10
10秒前
XX完成签到,获得积分10
10秒前
山猫完成签到,获得积分10
11秒前
开心人达发布了新的文献求助10
11秒前
12秒前
Cecily发布了新的文献求助10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969383
求助须知:如何正确求助?哪些是违规求助? 3514211
关于积分的说明 11172730
捐赠科研通 3249476
什么是DOI,文献DOI怎么找? 1794909
邀请新用户注册赠送积分活动 875441
科研通“疑难数据库(出版商)”最低求助积分说明 804827